Clinical Utility of F-18-FDG PET/CT Concurrent with I-131 Therapy in Intermediate-to-High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Jeong Won | - |
dc.contributor.author | Lee, Sang Mi | - |
dc.contributor.author | Lee, Dae Ho | - |
dc.contributor.author | Kim, Yeo Joo | - |
dc.date.accessioned | 2021-08-12T01:12:27Z | - |
dc.date.available | 2021-08-12T01:12:27Z | - |
dc.date.issued | 2013-08 | - |
dc.identifier.issn | 0161-5505 | - |
dc.identifier.issn | 1535-5667 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13489 | - |
dc.description.abstract | Patients with differentiated thyroid carcinoma (DTC) are treated with I-131 therapy after total thyroidectomy or surgical resection of recurrent tumor. However, some recurrent DTC lesions are not iodine-avid, which affects further treatment planning. The aim of this study was to evaluate the clinical benefit of F-18-FDG PET/CT performed concurrently with I-131 therapy in DTC patients with intermediate to high risk. Methods: We retrospectively enrolled 286 DTC patients at 2 Korean medical centers who comprised 2 different patient groups: 28 patients who underwent adjuvant I-131 treatment after curative surgical resection of recurrent tumor and 258 patients with intermediate to high risk who underwent I-131 ablation after total thyroidectomy. I-131 therapy and F-18-FDG PET/CT scanning were performed on the same day. Administration of L-thyroxine was withheld from all enrollees for 4 wk before I-131 treatment. Results: In 39 patients (14%), F-18-FDG PET/CT detected additional recurrent or metastatic lesions that were not detected on the posttherapy I-131 scan, and the treatment plan was changed for 30 patients (10%) based on such findings. Among the 28 patients receiving I-131 treatment after resection of recurrent tumor, PET/CT detected additional lesions in 46%, and treatment was changed in 43%. Assessing a subgroup of stage T3-T4N1 patients with tumor size > 2.0 cm, among 258 patients undergoing I-131 ablation after total thyroidectomy, we found that 25% had additional positive PET/CT results, and treatment changed for 17%. In contrast, 8% of stage T3-T4N1 patients with tumor size <= 2.0 cm, 6% of stage T1-T2N1 patients, and 3% of stage T3-T4N0 patients had additional positive PET/CT findings. Conclusion: F-18-FDG PET/CT performed concurrently with I-131 therapy detected additional lesions in 14% of DTC patients and was particularly helpful for detecting additional lesions in patients undergoing I-131 therapy after resection of recurrent tumor or in stage T3-T4N1 patients with tumor size > 2.0 cm. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Kexue Chubaneshe/Science Press | - |
dc.title | Clinical Utility of F-18-FDG PET/CT Concurrent with I-131 Therapy in Intermediate-to-High-Risk Patients with Differentiated Thyroid Cancer: Dual-Center Experience with 286 Patients | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.2967/jnumed.112.117119 | - |
dc.identifier.scopusid | 2-s2.0-84881463696 | - |
dc.identifier.wosid | 000322692400028 | - |
dc.identifier.bibliographicCitation | Journal of Nuclear Medicine, v.54, no.8, pp 1230 - 1236 | - |
dc.citation.title | Journal of Nuclear Medicine | - |
dc.citation.volume | 54 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1230 | - |
dc.citation.endPage | 1236 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | POSITRON-EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | WHOLE-BODY SCAN | - |
dc.subject.keywordPlus | SERUM THYROGLOBULIN | - |
dc.subject.keywordPlus | RADIOIODINE THERAPY | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | CARCINOMA | - |
dc.subject.keywordPlus | PAPILLARY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordAuthor | differentiated thyroid cancer | - |
dc.subject.keywordAuthor | F-18-fluorodeoxyglucose | - |
dc.subject.keywordAuthor | positron emission tomography | - |
dc.subject.keywordAuthor | radioiodine therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.